Our partner Cayman Chemical is committed to leading efforts to develop MS-based approaches.
They tell you why.
Immunoassays to Mass Spectrometry: Transitioning Technology
Extract from Cayman Chemicals Assays Catalog
"In 1987, there was a need for an easy-to-use, low-waste, and cost-effective technique for the detection and quantification of small bioactive molecules.
Cayman Chemical responded to the research community by introducing one of the first commercially-available enzyme-linked immunosorbent assays (ELISAs) for prostaglandin E2 as an alternative to the cumbersome radioimmunoassay.
Almost 30 years later, Cayman continues to offer several ELISAs to researchers, constantly improving on the reliability and sensitivity of these assays. It is known that antibody-based techniques are limited by the specificity of the antibodies involved, which remains a challenge for researchers quantifying small molecules and biomolecules such as eicosanoids, proteins, and peptides.
Moreover, quantitation is limited to the antibody-specific antigen(s), usually a single analyte. Researchers and clinicians alike are now turning to mass spectrometry (MS) as an alternative analytical technique because of its advantages over ELISA-based methods. MS offers an inherent specificity advantage as well as multiplexing capabilities, albeit with significant start-up costs.
The value of rapidly quantifying multiple targets simultaneously with accuracy and certainty makes MS an increasingly popular method of choice. Cayman is committed to leading efforts to develop MS-based approaches, as we have done with ELISAs, and offers a variety of highly pure standards for analysis by MS.
Cayman’s team of scientists is dedicated to both ELISA and MS analyses to provide researchers worldwide with the tools and expertise needed to make research possible.